azacitidine / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

78 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azacitidine / Generic mfg.
NCT05148442: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Terminated
1a/1b
1
RoW
IBI322
Innovent Biologics (Suzhou) Co. Ltd.
Myeloid Tumor
06/23
08/23
M15-522, NCT02966782: A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Completed
1b
70
Europe, US, RoW
venetoclax, ABT-199, GDC-0199, azacitidine, Vidaza
AbbVie, Celgene; Genentech, Inc.
Myelodysplastic Syndromes (MDS)
04/23
04/23
5F9005, NCT03248479: Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Hourglass Jan 2022 - Mar 2022 : Data from trial for MDS
Checkmark Expanded efficacy and updated durability data from P1b trial in combination with azacitidine for AML
May 2020 - May 2020: Expanded efficacy and updated durability data from P1b trial in combination with azacitidine for AML
Checkmark Data from trial in combination with azacitidine in AML and MDS at ASH 2019
Dec 2019 - Dec 2019: Data from trial in combination with azacitidine in AML and MDS at ASH 2019
More
Terminated
1b
258
Europe, US
Magrolimab, Hu5F9-G4, Azacitidine, VIDAZA
Gilead Sciences
Hematological Malignancies
09/23
09/23
CPDR001X2105, NCT03066648: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Checkmark Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Jun 2020 - Jun 2020: Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Checkmark In combination with PDR001 for AML or high risk MDS
Feb 2017 - Feb 2017: In combination with PDR001 for AML or high risk MDS
Completed
1b
241
Europe, US, RoW
Decitabine, 5-aza-2'-deoxycytidine, PDR001, spartalizumab, MBG453, sabatolimab, Azacitidine, 5-azacytidine
Novartis Pharmaceuticals
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
09/23
09/23
ELEVATE, NCT04150887: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Hourglass Sep 2021 - Dec 2021 : P1b data from ELEVATE trial in combination with azacitidine and venetoclax for AML
Active, not recruiting
1b
61
Europe, Canada, US
Cusatuzumab, JNJ-74494550, ARGX-110, Azacitidine, Vidaza, Venetoclax, Venclexta
OncoVerity, Inc., argenx, Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
05/24
05/24
NCT05970822: Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Recruiting
1b
32
RoW
BC3402, Azacitidine
Biocity Biopharmaceutics Co., Ltd.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
03/25
12/25
NCT00336063: Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Active, not recruiting
1
18
Japan, US, RoW
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
04/13
03/25
2011-005023-40: A dose finding study of Romidepsin and Azacitidine in patients with Acute Myeloid Leukaemia (AML)

Ongoing
1
30
Europe
Romidepsin, Azacitidine, Vidaza, Vidaza
University of Birmingham, Celgene Ltd, Leukaemia & Lymphoma Research Trials Acceleration Programme (TAP)
Acute myeloid leukaemia (AML)
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
NCT03194932: Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Completed
1
62
US
Venetoclax, Venclextra®, ABT-199, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Idarubicin, Idamycin PFS, Intrathecal Triple Therapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Azacitidine, VIDAZA®
St. Jude Children's Research Hospital, Gateway for Cancer Research
Acute Myeloid Leukemia
10/20
06/22
NCT02038777: A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Completed
1
48
Japan
PF-04449913, Low dose ARA-C (LDAC), Daunorubicin, Cytarabine, Azacitidine, LDAC
Pfizer
Acute Myeloid Leukemia
02/21
12/23
TACTAL, NCT01333046: Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma;

Active, not recruiting
1
36
US
Antigen-Escalation Stage, T cell injection, Tumor-specific CTL lines, Dose-Escalation Stage, TAA-CTL infusion, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
09/21
09/27
ADVL1712, NCT03813147 / 2019-002935-27: Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
1
12
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, Hydrocortisone, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid
National Cancer Institute (NCI), Children's Oncology Group
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
09/21
12/23
ACTRN12614000810617: A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Active, not recruiting
1
42
 
Australasian Leukaemia and Lymphoma Group, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukaemia (FLT3-ITD positive)
 
 
COZMOS, NCT03206021: Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

Completed
1
31
Canada, US, RoW
5 Azacytidine, Carboplatin
The Hospital for Sick Children
Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor
08/22
03/24
ChiCTR2200058059: A prospective clinical study of Azacitidine combined with or without Venetoclax for the maintenance treatment of post-remission acute myeloid leukemia

Recruiting
1
80
 
Azacitidine ± Venetoclax
Peking University People's Hospital; Peking University People's Hospital, National Natural Science Foundation of China
Leukemia
 
 
ChiCTR2000040043: A phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of Azacitidine for injection combined with Chidamide in patients with relapsed/refractory T-cell lymphoma

Not yet recruiting
1
17
 
Dose group 1: azacitidine 50mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 2: azacitidine 75mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 3: azacitidine 50mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 4: Azacytidine 75mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle; ;RP2D
Tianjin Cancer Hospital; Tianjin Cancer Hospital, Tianjin Cancer Hospital
T cell lymphoma
 
 
NCT03513484: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
44
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef
Northwestern University, Robert H. Lurie Cancer Center, Boehringer Ingelheim, National Cancer Institute (NCI)
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/25
01/27
NCT04243785: A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
1
80
US
BTX-A51, Azacitidine
Edgewood Oncology Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
03/26
03/27
NCT03236857 / 2017-000439-14: A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Completed
1
143
Europe, Canada, US, RoW
chemotherapy, venetoclax, ABT-199, GDC-0199, Venclexta
AbbVie, Roche-Genentech
Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
04/23
04/23
NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Terminated
1
40
Europe, Japan, US, RoW
Lemzoparlimab, TJ011133, ABBV-IMAB-TJC4, Azacitidine, Venetoclax, Venclexta, Venclyxto, ABT-199, GDC-0199
AbbVie
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
05/23
05/23
NCT04603001: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Active, not recruiting
1
260
Europe, Canada, US, RoW
LY3410738, Venetoclax, Azacitidine
Eli Lilly and Company, Loxo Oncology, Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
07/23
05/25
NCT05426798: Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Recruiting
1
73
RoW
TQB2618 injection azacitidine, AZA decitabine, DAC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
09/23
12/23
NCT03326310: Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Recruiting
1
18
US
Azacitidine, Vidaza, Selumetinib, AZD6244
University of Chicago
Chronic Myeloid Leukemia, Myelofibroses
09/25
09/25
NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Terminated
1
22
Europe, Canada, US
CC-90009, Venetoclax, Azacitidine, Gilteritinib
Celgene, AbbVie
Leukemia, Myeloid, Acute
10/23
04/24
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed
1
37
US
STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/24
03/24
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT04512105: Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Active, not recruiting
1
6
US
Pitavastatin, LIVALO®, Venetoclax, VENCLEXTA®
University of California, Irvine, United States Department of Defense
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
04/23
06/24
NCT02675452: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
142
Europe, Canada, Japan, US, RoW
AMG 176, Study Investigational Product (IP), Azacitidine, Itraconazole
Amgen
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
06/24
06/24
NCT04485065: Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Suspended
1
120
RoW
IBI188+azacitidine
Innovent Biologics (Suzhou) Co. Ltd.
Myelodysplastic Syndromes
12/23
08/24
NCT05659992: Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
30
RoW
azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
Chinese PLA General Hospital
Acute Myeloid Leukemia
01/24
01/24
ChiCTR2200065634: One arm open phase I clinical study of Venetoclax combined with CACAG regimen in the treatment of acute myeloid leukemia

Recruiting
1
30
 
1.azacytidine (75mg/m2/day, days 1 to 7). 2.cytarabine (75mg/m2 bid, days 1 to 5). 3.aclamycin (10mg/m2/day, day1,3,5). 4.Chidamide (30mg/day , days 0,3). 5.venetoclax (100mg day 1, 200 mg day 2, 400mg days 3 to 14 ). 6.granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery
Chinese PLA General Hospital; Chinese PLA General Hospital, Fully self-raised
acute myeloid leukemia
 
 
NCT03613532: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Recruiting
1
100
US
Venetoclax, ABT199, Fludarabine, Fludara, Busulfan, Busulfex, Myleran, Azacitidine, Decitabine/cedazuridine
Jacqueline Garcia, MD, National Institutes of Health (NIH)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
02/25
02/26
03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/25
12/25
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Active, not recruiting
1
177
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
09/24
09/24
NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
24
US
Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®
St. Jude Children's Research Hospital, Syndax Pharmaceuticals
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
01/26
07/26
NCT06377085: Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy

Not yet recruiting
1
27
NA
Placebo for the AZA 10mg/m^2, Placebo for the AZA 20mg/m^2, Placebo for the AZA 35mg/m^2, Placebo for the AZA 75mg/m^2, 5-Azacytidine 10mg/m^2, 5-Azacytidine 20mg/m^2, 5-Azacytidine 35mg/m^2, 5-Azacytidine 75mg/m^2
Shirley Ryan AbilityLab, Rady Children's Hospital, San Diego
Cerebral Palsy, Contracture
05/26
05/26
AML-VAC-XS15, NCT06252584: Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

Not yet recruiting
1
20
NA
Vaccines, Peptide, Multipeptide Vaccine AML-VAC-XS15
University Hospital Tuebingen
Acute Myeloid Leukemia, Adult
05/26
11/26
CR109124, NCT05453903: A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Recruiting
1
150
Europe, US, RoW
JNJ-75276617, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
05/24
03/26
NCT06285890: Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
18
US
HC-7366, Azacitidine, Ladakamycin, AZA-CR, NSC-102816, Azacytidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center, HiberCell, Inc.
Acute Myeloid Leukemia
12/27
12/29
NCT03113643: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Hourglass Jan 2021 - Mar 2021 : From trial for CD123 enriched AML
Hourglass Jul 2020 - Sep 2020 : Data from trial for 1L and relapsed/refractory AML or high-risk MDS
Recruiting
1
72
US
Azacitidine, Vidaza, SL-401, Venetoclax, Venclyxto, Venclexta
Dana-Farber Cancer Institute, Stemline Therapeutics, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
05/25
05/26
NCT03843528: Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Recruiting
1
15
US
Vorinostat, Azacitidine Injection
Johns Hopkins All Children's Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia
07/24
10/24
HR-MDS, NCT02942290 / 2016-001657-41: A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Checkmark Data from trial in combination with azacitidine for high risk MDS at ASH 2021
Dec 2021 - Dec 2021: Data from trial in combination with azacitidine for high risk MDS at ASH 2021
Active, not recruiting
1
129
Europe, Canada, US, RoW
Azacitidine, Venetoclax, ABT-199, GDC-0199, VENCLEXTA
AbbVie, Genentech, Inc.
Myelodysplastic Syndromes (MDS)
01/27
01/27
NCT06357182: Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
24
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
OHSU Knight Cancer Institute, Oregon Health and Science University, Oryzon Genomics S.A.
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
03/26
05/26
NCT04964505: Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Recruiting
1
25
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Uproleselan, GMI-1271, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Brian Jonas, GlycoMimetics Incorporated, National Cancer Institute (NCI)
Acute Myeloid Leukemia
07/24
01/25
NCT06466798: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Not yet recruiting
1
10
US
Nivolumab, Methotrexate, 5-Azacytidine
David Ilan Sandberg
Recurrent Ependymoma, Recurrent Medulloblastoma, CNS Malignancies
07/27
07/27
NCT06158100: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Not yet recruiting
1
25
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Vidaza, Azadine, Donor Lymphocyte Infusion
Antonio M Jimenez Jimenez, AbbVie
Acute Myeloid Leukemia
07/29
07/29
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Recruiting
1
36
US
DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto
Kahr Medical
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/24
12/24
NCT06397027: A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Not yet recruiting
1
22
US
Ziftomenib, Venetoclax, ABT-199, GDC-0199, Azacitidine, 5-azacytidine,, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, Azacytidine, NSC-102816
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Refractory Acute Leukemia, Pediatric Relapsed
12/28
12/30
NCT06445907: Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Not yet recruiting
1
32
US
Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine, Venetoclax, ABT-199, GDC-0199, Q702
M.D. Anderson Cancer Center, Qurient Co., Ltd.
Acute Myeloid Leukemia
07/26
07/28
PAVE, NCT04172844: Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Terminated
1
16
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924
Medical College of Wisconsin
Acute Myelogenous Leukemia
12/21
02/22
NCT04187703: 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Recruiting
1
20
US
5-azacytidine, azacytidine, Decitabine, 5-aza-2'-deoxycytydine
Benjamin Tomlinson
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
12/24
12/25
NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting
1
198
RoW
LP-108, Azacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
12/24
12/25
NCT04139434: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Active, not recruiting
1
36
Europe, US
LP-108, LP-108 and azacitidine
Newave Pharmaceutical Inc
AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
01/25
01/25
NCT05829226: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting
1
90
US
LYT-200, Venetoclax, Azacitidine, Decitabine
PureTech
AML, Adult Recurrent, MDS
02/25
05/25
NCT06454409: Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Not yet recruiting
1
20
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Regorafenib, BAY 73-4506, Regorafenib Anhydrous, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
02/27
02/27
NCT05292664: Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting
1
92
US
Venetoclax, Venclexta, Azacitidine, Vidaza, Cytarabine, Ara-C, Arabinosylcytosine, Methotrexate, Amethopterin, Methotrexate Sodium, MTX, Hydrocortisone, Cortisone, Hydrocortisone Sodium Succinate, Hydrocortisone Sodium Phosphate, Leucovorin, Calcium Leucovorin,, Citrovorum Factor, Folinic Acid, Dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, Vincristine, Vincristine Sulfate, LCR, VCR, Doxorubicin, Adriamycin, Rubex, Dexrazoxane, Zinecard, Calaspargase Pegol, Asparlas, Erwinia asparaginase, Rylze or native Erwinia asparaginase
Andrew E. Place, MD, AbbVie, Servier, Children's Cancer Research Fund, University of Colorado, Denver, Boston Children's Hospital, Gateway for Cancer Research
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
04/25
04/27
NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Terminated
1
21
US
PRT1419, Azacitidine, Venetoclax
Prelude Therapeutics
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
01/24
01/24
NCT05744440: Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT

Recruiting
1
12
RoW
allogenic NK cells
Xuzhou Medical University
Acute Myeloid Leukemia
05/25
05/25
NCT06008405: Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Recruiting
1
48
RoW
TQB2928 Injection + Azacitidine for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
05/25
05/25
NCT05155709 / 2021-001165-21: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Active, not recruiting
1
14
Europe, US, RoW
siremadlin, HDM201, venetoclax, azacitidine
Novartis Pharmaceuticals, Novartis Pharma AG
Acute Myeloid Leukemia
05/24
05/24
NCT05823480: Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS

Suspended
1
44
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, Magrolimab, Hu5F9-G4, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/25
05/25
ChiCTR2300072324: An open, single-arm study of azacytidine with R-CHOP (ARCHOP) for TP53 mutated de novo diffuse large B-cell lymphoma

Recruiting
1
52
 
ARCHOP
the First Affiliated Hospital of Xiamen University; the First Affiliated Hospital of Xiamen University, none
diffuse large B cell lymphoma
 
 
POLARIS2020-002, NCT05001828: Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Recruiting
1
60
US
ADI-PEG 20, Venetoclax, Azacitidine
Polaris Group
Acute Myeloid Leukemia, Adult
07/25
12/25
HSC-MS-21-0231, NCT04958486: Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma

Recruiting
1
10
US
5-Azacytidine and trastuzumab infusion
The University of Texas Health Science Center, Houston
Fossa Ependymoma
12/25
12/25
NCT05720988: Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Withdrawn
1
29
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS
Jonsson Comprehensive Cancer Center, Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
08/25
08/26
NCT05317000: 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Recruiting
1
50
US
Combination 5-azacytidine and nivolumab, Vidaza and Opdivo, 5-azacytidine, Vidaza, Nivolumab, Opdivo
Barbara Burtness
Squamous Cell Carcinoma of Head and Neck
09/25
02/26
NCT05476770: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting
1
54
US, RoW
Tagraxofusp, Elzonris, Fludarabine, Cytarabine, Cytosar, Dexamethasone, Decadron, Vincristine, Oncovin, Azacitidine, AZA, Vidaza, Methotrexate, MTX, Amethopterin, Cytarabine IT, Hydrocortisone
Therapeutic Advances in Childhood Leukemia Consortium
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
11/25
11/27
NCT03572530: Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma

Recruiting
1
9
US
5-Azacytidine (5-AZA) group 1, Vidaza, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
The University of Texas Health Science Center, Houston
Recurrent Ependymoma
12/25
12/25
NCT05209152: AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Completed
1
7
US
AMG 176, Azacitidine
Amgen
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
12/23
12/23
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Recruiting
1
102
RoW
APG-115, Azacitidine, Cytarabine
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
12/25
12/25
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
NCT05168202: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Active, not recruiting
1
218
Europe, Canada, US, RoW
CC-95251, BMS-986351, Azacitidine, Venetoclax
Bristol-Myers Squibb
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
06/26
06/26
ADVENT-AML, NCT05834244: A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia

Recruiting
1
32
US
Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine, Venetoclax, ABT-199, GDC-0199, NK Cells
M.D. Anderson Cancer Center
Acute Myeloid Leukemia
06/26
06/28
eDC-MDS, NCT04999943: Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Recruiting
1
40
RoW
DC vaccine
Affiliated Hospital to Academy of Military Medical Sciences
Myelodysplastic Syndromes, Dendritic Cell, Hypomethylating Agents, Immunotherapy
07/26
07/26
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Recruiting
1
430
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
NCT05317403: Venetoclax to Augment Epigenetic Modification and Chemotherapy

Recruiting
1
40
US
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Medical College of Wisconsin
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/26
01/27

Download Options